TRUOZA Trademark

Trademark Overview


On Wednesday, July 7, 2021, a trademark application was filed for TRUOZA with the United States Patent and Trademark Office. The USPTO has given the TRUOZA trademark a serial number of 90815184. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Thursday, October 9, 2025. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The TRUOZA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
truoza

General Information


Serial Number90815184
Word MarkTRUOZA
Filing DateWednesday, July 7, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateThursday, October 9, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 21, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Friday, November 12, 2021ASSIGNED TO EXAMINER
Friday, November 12, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, July 10, 2021NEW APPLICATION ENTERED
Wednesday, September 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 21, 2021PUBLISHED FOR OPPOSITION
Tuesday, December 21, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 26, 2022SOU EXTENSION 1 GRANTED
Wednesday, December 1, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 26, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 26, 2022SOU EXTENSION 1 FILED
Thursday, July 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 2, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, February 6, 2023SOU EXTENSION 2 FILED
Monday, February 6, 2023SOU EXTENSION 2 GRANTED
Wednesday, August 2, 2023SOU TEAS EXTENSION RECEIVED
Thursday, February 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 6, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 8, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023SOU EXTENSION 3 FILED
Wednesday, August 2, 2023SOU EXTENSION 3 GRANTED
Monday, March 18, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, August 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 15, 2024SOU EXTENSION 4 FILED
Monday, March 18, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, March 19, 2024TEAS PETITION TO REVIVE RECEIVED
Tuesday, March 19, 2024TEAS PETITION TO REVIVE RECEIVED
Tuesday, March 19, 2024PETITION TO REVIVE-GRANTED
Tuesday, March 19, 2024NOTICE OF REVIVAL - E-MAILED
Tuesday, March 19, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Wednesday, August 14, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, April 30, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, May 1, 2024SOU EXTENSION 4 GRANTED
Thursday, May 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 14, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 14, 2024SOU EXTENSION 5 FILED
Wednesday, August 14, 2024SOU EXTENSION 5 GRANTED
Thursday, October 9, 2025ABANDONMENT - NO USE STATEMENT FILED
Thursday, October 9, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED